摘要
非小细胞肺癌的治疗在过去的20多年里有了相当大的进步，化疗相比支持治疗更能使总体受益。第三代以铂类为基础的两药联用方案已经确立，无铂方案也在发展。化疗已经广泛用于那些以前被认为不适用化疗的患者，化疗持续时间也变得更短，而疗效相当。在认识到化疗所带来的益处之后，出现了一些具有新颖作用机制的新药。本文就目前化疗的概况、方案，以及靶向治疗、新化疗药物的进展作一综述。
Management of non small cell lung cancer has improved considerably in the past two decades. The overall benefit of chemotherapy over supportive care has been shown, platinum-based doublets have been established, nonplatinum regimens have been developed,chemotherapy has been used more broadly in subgroups of patients who have been previously neglected,and a shorter chemotherapy duration has been shown to be equally effective. After hitting a plateau in the benefit of chemotherapy, new drugs with novel action mechanisms offer hope to improve therapy for this disease. This paper reviews the most significant changes seen in chemotherapy, targeted therapies, and the most promising new agents in development for this disease.
出处
《国际呼吸杂志》
2008年第18期1146-1149,共4页
International Journal of Respiration
关键词
非小细胞肺癌
靶向治疗
化学治疗
Non-small cell lung cancer
Targeted therapy
Chemotherapy
